Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule
Dodion, P., Rozencweig, M., Nicaise, C., Piccart, M., Cumps, E., Crespeigne, N., Kisner, D., Kenis, Y.Volume:
18
Language:
english
Journal:
European Journal of Cancer and Clinical Oncology
DOI:
10.1016/0277-5379(82)90220-6
Date:
June, 1982
File:
PDF, 382 KB
english, 1982